A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study

Trial Profile

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ELEMENT 5
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Jun 2017 Primary endpoint (Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c)) has been met, according to results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top